Biohaven Pharmaceutical Holding Co Ltd.

Industry group: Drugs

Headquarters: Connecticut

Overview

Average pay of disclosed executives at Biohaven Pharmaceutical Holding Co Ltd.

Annual data

2018

On April 11, 2019, Biohaven Pharmaceutical Holding Co Ltd. reported executive compensation for fiscal year 2018.

NamePositionCompensationDetails
Vlad CoricChief Executive Officer$7,854,000
James EngelhartChief Financial Officer$3,217,068
Charles ConwayChief Scientific Officer$2,792,855
Kimberly GentileSVP, Clinical Operations$2,784,539
John TiltonChief Commercial Officer$1,525,674

Vlad Coric — Chief Executive Officer — received the highest compensation: $7,854,000 in total.

In addition, James Engelhart — Chief Financial Officer — received a total compensation of $3,217,068; Charles Conway received $2,792,855; Kimberly Gentile received $2,784,539; John Tilton received $1,525,674.

2017

On March 29, 2018, Biohaven Pharmaceutical Holding Co Ltd. reported executive compensation for fiscal year 2017.

NamePositionCompensationDetails
Vlad CoricChief Executive Officer$3,855,665
James EngelhartChief Financial Officer$2,510,283
Charles ConwayChief Scientific Officer$1,626,148

Vlad Coric — Chief Executive Officer — received the highest compensation: $3,855,665 in total.

In addition, James Engelhart — Chief Financial Officer — received a total compensation of $2,510,283; Charles Conway received $1,626,148.

2016

NamePositionCompensationDetails
Vlad CoricChief Executive Officer$784,428
James EngelhartChief Financial Officer$482,823

Vlad Coric — Chief Executive Officer — received the highest compensation: $784,428 in total.

In addition, James Engelhart — Chief Financial Officer — received a total compensation of $482,823.